Red Light Therapy: A Potential Solution for Reducing Alzheimer’s Risk
by Rohan Smith | Functional Medicine Practitioner | Adelaide, SA
Quick Answer
Red light therapy, also known as photobiomodulation, is being investigated for its potential role in supporting brain health in individuals at risk of Alzheimer’s disease. Research suggests it may influence key biological processes involved in neurodegeneration, including mitochondrial function, oxidative stress, and neuroinflammation. While current evidence is preliminary and largely experimental, red light therapy is an emerging area of interest within Alzheimer’s research (1–3).
Understanding Alzheimer’s Disease
Alzheimer’s disease is a progressive neurodegenerative condition characterised by the accumulation of beta-amyloid plaques and tau protein tangles within the brain. These abnormal protein aggregates interfere with neuronal communication, contribute to synaptic dysfunction, and ultimately lead to memory impairment and cognitive decline (4–6).
Although the exact cause of Alzheimer’s disease remains incompletely understood, multiple contributing factors have been identified, including age-related changes, genetic susceptibility, metabolic dysfunction, chronic inflammation, and oxidative stress. These overlapping processes create a complex disease pathway rather than a single causative trigger (7–9).
Red Light Therapy: A Novel Approach
Red light therapy involves exposure to low-level red or near-infrared light at specific wavelengths. This form of photobiomodulation is designed to stimulate cellular processes involved in energy production and tissue repair. In neurological research, attention has focused on its potential effects on brain cells affected by neurodegenerative disease processes (1,3).
In the context of Alzheimer’s disease, red light therapy is being explored as an adjunctive strategy aimed at supporting cellular resilience rather than as a standalone treatment.
How Red Light Therapy Works
One of the primary biological targets of red light therapy is the mitochondria, the structures responsible for producing cellular energy in the form of adenosine triphosphate (ATP). Adequate mitochondrial function is essential for neuronal health, synaptic activity, and cellular repair mechanisms (10,11).
By influencing mitochondrial activity, red light therapy may enhance ATP production and improve cellular energy availability. In addition, photobiomodulation has been shown to modulate oxidative stress and inflammatory signalling pathways, both of which are implicated in neurodegenerative disease progression (12,13).
Chronic neuroinflammation and oxidative damage are recognised contributors to neuronal injury in Alzheimer’s disease. Interventions that influence these pathways are therefore of interest in research aimed at slowing functional decline and are frequently explored in the context of chronic fatigue and neuroimmune conditions (14).
Evidence Supporting Red Light Therapy in Alzheimer’s Research
1. Cognitive Function
Early-stage human studies investigating transcranial red and near-infrared light exposure have reported modest improvements in certain cognitive domains among individuals with mild cognitive impairment. These findings are preliminary and based on small study populations, but they suggest a possible role for photobiomodulation in cognitive support (15–17).
2. Beta-Amyloid Accumulation
Preclinical studies using animal models of Alzheimer’s disease have demonstrated reductions in beta-amyloid burden following red light therapy exposure. These findings suggest that photobiomodulation may influence protein clearance pathways involved in plaque accumulation, although translation to human outcomes remains under investigation (18,19).
3. Neuroprotective Effects
Laboratory and animal studies indicate that red light therapy may support neuronal survival and synaptic plasticity. Synaptic plasticity refers to the brain’s ability to adapt and reorganise neural connections, a function that is progressively impaired in Alzheimer’s disease (20,21).
4. Proposed Mechanisms
The precise mechanisms underlying photobiomodulation’s effects in neurodegenerative conditions are still being explored. Current hypotheses focus on mitochondrial modulation, reduction of oxidative stress, regulation of inflammatory pathways, and support of neuronal signalling processes (3,10).
The Path Forward
Red light therapy represents an area of growing scientific interest in Alzheimer’s research, particularly as an adjunctive approach aimed at supporting cellular and metabolic brain health. However, it remains an experimental intervention and should be viewed within the context of ongoing research rather than as a preventive or disease-modifying therapy.
Optimising brain health requires a comprehensive approach that considers metabolic health, inflammation, nutrient status, sleep, and lifestyle factors. Functional medicine approaches focus on identifying contributing imbalances and supporting overall physiological resilience through personalised strategies, including assessment of the gut–brain axis.
Frequently Asked Questions
Can red light therapy prevent or treat Alzheimer’s disease?
No. Red light therapy is not a proven preventive or treatment for Alzheimer’s disease. Current research is preliminary and largely experimental. Photobiomodulation is being explored as a supportive, adjunctive strategy that may influence biological processes involved in neurodegeneration, rather than as a disease-modifying therapy.
Who might be most interested in red light therapy research for brain health?
Research interest has primarily focused on individuals with mild cognitive impairment or those at increased risk of neurodegenerative decline. However, potential relevance appears to depend on underlying factors such as mitochondrial dysfunction, oxidative stress, and neuroinflammation, rather than diagnosis alone.
Is red light therapy safe for brain health applications?
Red light therapy is generally considered low risk when used within researched parameters, but clinical standards for neurological use are still evolving. It should not be undertaken without appropriate guidance, particularly in individuals with neurological conditions or complex medical histories.
Key Takeaways
Alzheimer’s disease involves complex, multi-factorial processes including mitochondrial dysfunction, inflammation, and oxidative stress.
Red light therapy (photobiomodulation) is being investigated for its potential to support cellular energy production and neuroprotective pathways.
Human evidence remains limited, with current findings considered preliminary and exploratory.
Photobiomodulation is best viewed as an adjunctive, experimental approach rather than a preventive or therapeutic intervention.
Long-term brain health is best supported through a comprehensive strategy addressing metabolic health, inflammation, sleep, nutrition, and lifestyle factors.
Next Steps
If you are experiencing cognitive concerns or wish to take a proactive approach to long-term brain health, a personalised assessment may help identify contributing factors that can be addressed through evidence-informed lifestyle and nutritional strategies. Working with a qualified healthcare practitioner ensures that emerging therapies are considered appropriately and safely within a broader care framework, such as a functional medicine approach to brain health.
References
- Hamblin MR. Photobiomodulation for the treatment of Alzheimer’s disease. J Alzheimers Dis. 2016.
- Caldieraro MA, Cassano P. Transcranial photobiomodulation for neuropsychiatric disorders. Psychiatr Clin North Am. 2019.
- Salehpour F et al. Photobiomodulation therapy for cognitive decline. J Photochem Photobiol B. 2018.
- Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010.
- De Strooper B, Karran E. The cellular phase of Alzheimer’s disease. Cell. 2016.
- Jack CR et al. NIA-AA research framework. Alzheimers Dement. 2018.
- Heneka MT et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015.
- Swerdlow RH. Mitochondria and mitochondrial cascades in Alzheimer’s disease. J Alzheimers Dis. 2018.
- Cunnane SC et al. Brain fuel metabolism in aging and Alzheimer’s disease. Nutrients. 2020.
- Rojas JC, Gonzalez-Lima F. Low-level light therapy of the brain. Front Neurosci. 2011.
- Cardoso SM et al. Mitochondrial dysfunction in Alzheimer’s disease. Neurochem Res. 2016.
- Hamblin MR. Mechanisms of low-level light therapy. Photochem Photobiol. 2017.
- Chung H et al. The nuts and bolts of low-level light therapy. Ann Biomed Eng. 2012.
- Morris G et al. The role of inflammation in neuroimmune fatigue syndromes. Mol Neurobiol. 2015.
- Berman MH et al. Transcranial photobiomodulation improves cognition. Neurosci Med. 2017.
- Saltmarche AE et al. Significant cognitive improvements following transcranial PBM. Photomed Laser Surg. 2017.
- Chao LL. Effects of home-based transcranial PBM. J Alzheimers Dis. 2019.
- Lu Y et al. Near-infrared light reduces amyloid-beta in AD mice. Sci Rep. 2017.
- Purushothuman S et al. Photobiomodulation mitigates amyloid pathology. Alzheimers Res Ther. 2014.
- Mohammed HS et al. PBM improves neuronal survival in neurodegeneration. Lasers Med Sci. 2017.
- Farivar S et al. Biological effects of low-level laser therapy. Lasers Med Sci. 2014.